About: Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease
Creator	Torres, Juan Baâ Rcena A , Beleâ N Vaâ Zquez, Juan Espunä, Enric Pageá S-Manteâ, Albert Ramõâ Rez A , Moâ Nica Morales, Miguel Saâ Nchez-Vizcaõâ No, Joseâ
Source	Elsevier; Medline; PMC
abstract	Abstract We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114–23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.
has issue date	2000-09-15(xsd:dateTime)
bibo:doi	10.1016/s0264-410x(00)00183-3
bibo:pmid	10930670
has license	els-covid
sha1sum (hex)	0beba87e3366b16efad5fc85a9fb2be33e63e019
schema:url	https://doi.org/10.1016/s0264-410x%2800%2900183-3
resource representing a document's title	Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease
has PubMed Central identifier	PMC7125741
has PubMed identifier	10930670
schema:publication	Vaccine
resource representing a document's body	covid:0beba87e3366b16efad5fc85a9fb2be33e63e019#body_text
is schema:about of	named entity 'VACCINE ADMINISTRATION' named entity 'INDICATED' named entity 'CHALLENGES' named entity 'HORIZONTAL' named entity 'HAVE' named entity 'PROPOSED' named entity 'IN VIVO' named entity 'USING' named entity 'HAEMORRHAGIC' named entity 'ADMINISTRATION' named entity 'CONSIDERING' named entity 'RABBIT HAEMORRHAGIC DISEASE VIRUS' named entity 'rabbit haemorrhagic disease virus' named entity 'transmissible' named entity 'attenuated' named entity 'overdose' named entity 'administration' named entity 'fold' named entity 'Safety' named entity 'evaluation' named entity 'RHDV' named entity 'DISEASE' named entity 'INDUCING' named entity 'PREGNANT' named entity 'USE' named entity 'PHENOTYPE' named entity 'HAEMORRHAGIC' named entity 'MYXOMATOSIS' named entity 'HORIZONTAL' named entity 'MAINTAINED' named entity 'EVALUATED' named entity 'WILD RABBIT' named entity '2000' named entity 'SAFE' named entity 'MYXOMA VIRUS' named entity 'VIROL' named entity 'RABBITS' named entity 'RISKS' named entity 'IMMUNOSUPPRESSED' named entity 'ITS' named entity 'PROMOTING' named entity 'LETHAL' named entity 'OVERDOSE' named entity 'MYXOMA' named entity 'RECOMBINANT' named entity 'PROTECTION' named entity 'SAFETY EVALUATION' named entity 'RABBIT' named entity 'CONDITIONS' named entity 'RESULTS' named entity 'SPREADING' named entity 'MYXOMATOSIS' named entity 'PROTEIN ' named entity 'BASED' named entity 'OPPORTUNITY' named entity 'PROVIDING' named entity 'LABORATORY' named entity 'ATTENUATED' named entity 'CAPABLE' named entity 'CONTACT' named entity 'VIRUS' named entity 'RECOMBINANT' named entity 'FOLD' named entity 'PROTECTION' named entity 'RECENTLY' named entity 'SAFETY ISSUES' named entity 'RECOMBINANT VIRUS' named entity 'POTENTIAL' named entity 'STUDY' named entity 'DISEASE' named entity 'CAPSID PROTEIN' named entity 'POPULATIONS' named entity '100' named entity 'ANIMALS' named entity 'DETECTED' named entity 'VACCINE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software